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The myogenic factor MyoD regulates skeletal muscle differentiation by interacting with a variety of 
chromatin‑modifying complexes. Although MyoD can induce and maintain chromatin accessibility 
at its target genes, its binding and trans‑activation ability can be limited by some types of not fully 
characterized epigenetic constraints. In this work we analysed the role of PARP1 in regulating MyoD‑
dependent gene expression. PARP1 is a chromatin‑associated enzyme, playing a well recognized 
role in DNA repair and that is implicated in transcriptional regulation. PARP1 affects gene expression 
through multiple mechanisms, often involving the Poly(ADP‑ribosyl)ation of chromatin proteins. In 
line with PARP1 down‑regulation during differentiation, we observed that PARP1 depletion boosts the 
up‑regulation of MyoD targets, such as p57, myogenin, Mef2C and p21, while its re‑expression reverts 
this effect. We also found that PARP1 interacts with some MyoD‑binding regions and that its presence, 
independently of the enzymatic activity, interferes with MyoD recruitment and gene induction. We 
finally suggest a relationship between the binding of PARP1 and the loss of the activating histone 
modification H3K4me3 at MyoD‑binding regions. This work highlights not only a novel player in the 
epigenetic control of myogenesis, but also a repressive and catalytic‑independent mechanisms by 
which PARP1 regulates transcription.
Skeletal muscle differentiation is determined by the activation of a complex program of gene expression, which 
involves the temporally regulated induction of muscle-specific genes as well as of cell cycle inhibitors that ensure 
cell cycle exit of differentiating  cells1. The entire process is promoted by MyoD, a muscle-specific transcription 
factor recognized as the master regulator of myogenesis, due to its capability of converting several non-muscle 
cell types to skeletal muscle  cells2. MyoD regulates gene expression through a number of different and interde-
pendent mechanisms, which are being increasingly discovered in the last  years3,4. MyoD is a bHLH protein and 
interacts with most of its transcriptional targets by recognizing E-box  sequences5. The induction of transcription 
by MyoD relies on its cooperation with other transcription factors, both ubiquitous and muscle-specific, and 
on its ability to interact with chromatin modifying  enzymes1. The best established mechanisms by which the 
myogenic factor creates a chromatin environment permissive for transcription involves the recruitment of the 
histone acetylases p300/CBP and  pCAF6–8 and the chromatin remodelling complex SWI/SNF9,10 on the targeted 
regulatory-regions. Moreover, MyoD functionally interacts with the arginine methyltransferase  Prmt511, with 
the lysine methyltransferase Set7/912, with the chromatin remodelling enzyme  Chd213 and, as more recently 
reported, with the regulatory Long noncoding RNAs Linc-RAM14 and  Kcnq1ot115. MyoD has been shown to 
modify the chromatin status not only at promoters and enhancers, but also at intergenic  regions6. In this regard, 
using the p57/KvDMR1 locus 16 as a model, we provided evidence that MyoD can regulate gene expression from 
a distance by releasing repressive chromatin  loops17–19. More recently, a direct role of MyoD in reorganizing the 
three-dimensional chromatin interactome during the myogenic conversion, has been  reported20.
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Although MyoD can initiate chromatin remodeling and histone modifications at target sites in heterochroma-
tin, nevertheless its binding and transactivation capability are limited by some types of epigenetic constraints. In 
this regard, the poor ability of MyoD to convert some cell types to the muscle lineage has been ascribed, at least 
in part, to pre-existing chromatin features that preclude MyoD access to its  targets5,21. For example, it has been 
reported that trimethylation of lysine 27 on histone H3 (H3K27me3) at the regulatory regions of certain muscle-
specific genes prevents MyoD binding and gene activation in undifferentiated myoblasts. Upon differentiation 
stimuli, the recruitment of MyoD is enabled by the reduction of H3K27me3 levels, due to the down-regulation 
of EZH2, the histone methyltransferase that catalyzes this  modification22. Similarly, the access of MyoD to a 
number of differentiation genes, before the onset of differentiation, is blocked by a repressor complex containing 
Snail and the histone deacetylases I and II, which is removed only upon differentiation  stimuli23. The existence of 
epigenetic barriers for MyoD binding, involving EZH2 and H3K27me3, has also been suggested to contribute to 
the defective function of the myogenic factor in rhabdomyosarcoma  cells24. Moreover, we have recently shown 
that accumulation of H3 lysine 9 dimethylation (H3K9me2) at a critical regulatory region of the MyoD target 
p57kip2, hinders the binding of MyoD and the consequent reorganization of the chromatin architecture, thus 
preventing the up-regulation of the gene in muscle cell types un-responsive for p57  induction17. In light of the 
complexity of epigenetic regulation of transcription, it is most likely that the molecular mechanisms modulating 
MyoD binding to chromatin are even more various, an issue that awaits further investigation in relation to both 
physiological and pathological myogenesis.
PARP1 is the most abundant and the best studied family member of the Poly(ADP-ribose) polymerases 
(PARPs)25,26, also termed ADP-ribosyltransferases with diphtheria toxin homology (ARTDs), according to a new 
 nomenclature27. PARPs catalyze the addition of single or multiple ADP-ribose units on target proteins, using 
 NAD+ as a substrate, leading to Mono(ADP-ribosyl)ation or Poly(ADP-ribosyl)ation (PARylation)26. The addi-
tion of poly(ADP-ribose) (PAR) polymers is a reversible post-translational modification involved in a variety 
of cellular  processes28,29. PARP1 is localized predominantly in the  nucleus28 and, in part, in  mitochondria30 and 
catalyzes the PARylation of many different types of proteins, among which PARP1 itself, histones, transcription 
factors and other chromatin  proteins28,31.
The best recognized role of PARP1 is related to the maintenance of genome stability and relies on the modifi-
cation and recruitment of DNA repair complexes at sites of damaged DNA within  chromatin32. However, there is 
increasing evidence that PARP1 influences chromatin dynamics and transcription also in response to a variety of 
signals other than genotoxic stress, such as inflammation, proliferation and differentiation  stimuli26,33,34. PARP1 
has been reported to influence transcription through a variety of molecular mechanisms, with different outcomes 
on gene expression. It has long been recognized that PARP1 can directly affect the degree of chromatin compac-
tion. The active enzyme induces chromatin decondensation by causing nucleosomal-histone  PARylation35,36 and 
by displacing the linker histone H1 from  chromatin37,38. On the other hand, inactive PARP1 has been found to 
function as a structural component of chromatin and to cause chromatin compaction accompanied by tran-
scriptional  repression39–41.
PARP1 can also indirectly affect the chromatin structure by modulating the pattern of histone modifica-
tions and the DNA methylation  status42,43. For example, active PARP1 promotes histone acetylation at specific 
 promoters34,44 and supports histone phosphoacetylation at immediate early response genes during the emergency 
from  quiescence45. An additional strategy by which active PARP1 promotes chromatin accessibility, involves the 
inhibition of EZH2 activity, through PARylation of the histone methyltransferase, and the consequent decrease 
of the global levels of  H3K27me346,47. Moreover, PARP1-dependent PARylation also inhibits the histone dem-
ethylase KDM5B, resulting in the increased trimethylation of lysine 4 on histone H3 (H3K4me3)48, an active 
chromatin mark. On the other hand, inactive PARP1 was recognized to be a critical component of the core-
pressor complexes Groucho/TLE and CtBP, which block transcription from the MASH1 and p21 promoters 
 respectively49,50. According to a simple and elegant model, PARP1 would play a dual role in the transcriptional 
regulation, involving its participation in gene repression, when inactive, and then in gene de-repression, following 
the enzyme activation. In other words PARP-1 would function as an exchange factor promoting the switch from 
repression to activation in response to particular  signals39,49,50. Some findings, however, do not fit into this simple 
model. For example, active PARP1 participates in the establishment and maintenance of heterochromatin during 
X chromosome inactivation and ribosomal DNA silencing, as well as at telomeres and  centromeres51. Conversely, 
inactive PARP1 positively regulates a pluripotency gene expression program in embryonic stem  cells52.
To complicate the picture, PARP1 functions as a co-regulator of a number of sequence-specific transcription 
factors, acting in a multifaceted manner. Upon PARylation, some factors, such as YY1, p53, CREB, Sp1, SRY 
and C/EBPβ, lose the ability to bind to their recognition  sequences53,54. Some others, such as PPARγ, are instead 
 activated55. As a further strategy of co-regulation, PARP1, independently of its catalytic activity, interacts with 
and co-activates  E2F156 and  NFkB57.
As expected for such a pleiotropic regulator of transcription, it is emerging that PARP1 plays an important 
role in some developmental and differentiation  processes43,58. This function was initially underestimated, due to 
the absence of evident phenotypes, apart from the hypersensitivity to DNA damage, in PARP1 knock-out mice, 
probably as a consequence of redundant and/or compensatory roles of other PARP family  members59. Further 
investigations, based on cellular models of differentiation, demonstrated that PARP1 regulates gene expression 
at least during  adipogenesis60,  osteoclastogenesis61 and neuronal  differentiation49, as well as during induced 
 pluripotency52,62. Despite the large amount of evidence that PARP1 modulates different epigenetic events, most of 
which also play critical roles in MyoD-dependent transcription, little, if any, is known about the roles of PARP1 in 
muscle cells, apart from the impact of PARP activity on the cellular bioenergetics of differentiated  myotubes63,64.
In the present work we provide evidence that PARP1 participates in the transcriptional control of some 
paradigmatic examples of MyoD target genes by interfering, independently of its catalytic activity, with the 
recruitment of this myogenic factor to their regulatory regions within chromatin.
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Results
PARP1 represses MyoD‑target gene expression during muscle differentiation. It has been pre-
viously reported that PARP1 expression is down-regulated during muscle differentiation, allowing differentiated 
myotubes to acquire resistance to oxidative  stress63. According to this observation, and as shown in Supplemen-
tary Fig. S1, we found that PARP1 protein levels significantly decrease during the differentiation of C2.7 muscle 
cells, a well-established and reliable in vitro model of myogenesis, in concomitance with the induction of p57 
and myogenin, two examples of direct MyoD targets. This observation hinted at a possible involvement of PARP1 
in the control of the muscle differentiation process. To explore this hypothesis, we first examined the effects of 
PARP1 depletion on muscle gene expression in C2.7 cells stably knocked-down for PARP1. For this purpose, we 
employed a short hairpin RNA for PARP1 (shPARP1) cloned into a retroviral vector as previously  described45. 
Cell pools stably transduced with the shPARP1 or the empty control vector were isolated by puromycin selection 
and tested for the knockdown efficiency. As reported in Fig. 1a, shPARP1 cells displayed markedly reduced levels 
of the protein in proliferation conditions and almost undetectable levels in differentiation conditions, compared 
to control cells. Remarkably, as reported in Fig. 1b, the knock-down of PARP1 correlated with an increased 
induction of p57 and myogenin expression in differentiated cells. A similar effect was observed on the induction 
of p21, another Cip/Kip inhibitor, and of Mef2C, another muscle-regulatory factor, both directly up-regulated by 
MyoD at early stages of muscle  differentiation1. The observation that PARP1 depletion did not affect the basal, 
but only the induced expression of these genes, is easily explained by the well-established occurrence of multiple 
repressive mechanisms that prevent MyoD activity in proliferating  myoblasts65 and suggests that PARP1 partici-
pates in keeping under control the MyoD-target genes during the differentiation process.
To obtain a complementary evidence in support of a repressive role for PARP1 in muscle gene regulation, we 
analysed the effects of re-expressing the enzyme in PARP1-depleted myoblasts. To this end, we used a construct 
coding for human PARP1, taking advantage of the significant homology between human and mouse orthologs 
(about 92% of homology in the protein sequence and 87% in nucleotide sequence). This feature allows the correct 
function of the human protein in mouse cells and, at the same time, reduces the efficiency by which the short hair-
pin targets the exogenous PARP1 RNA. shPARP1 myoblasts were co-transfected with either the puc19—human 
PARP1 vector or with the empty vector, together with a selection vector containing the hygromycin resistance 
gene. Stable cell pools were selected by hygromycin treatment and first checked for the re-establishment of PARP1 
expression. As reported in Fig. 2a, PARP1 expression was restored, at levels comparable to the endogenous PARP1 
of control C2.7 cells (Fig.S2). Moreover MyoD levels, which are normally invariant during  differentiation65, were 
not affected at all by PARP1 (Fig. 2a). Remarkably, as shown in Fig. 2b, and conversely to the effect of PARP1 
depletion, PARP1 re-expression impaired the induction of p57, myogenin, p21 and Mef2C RNA levels, compared 
to shPARP1 control cells. It is interesting to note that the repression of p57, but not of the other genes, was clearly 
appreciable as early as 24 h after the shift to differentiation medium, indicating that this gene is more readily 
sensitive than the others to exogenous PARP1 expression. According to a well established model in which later 
myogenic markers require both MyoD and some of the early MyoD  targets66, PARP1 also affected the cell fusion 
into Myosin Heavy Chain (MHC)–positive myotubes, which is a later event of differentiation. This effect was 
observed both in depletion and in re-expression experiments (Fig. 2c and Supplementary Fig. S3). The impaired 
induction of MyoD targets was also observed in response to the transient over-expression of PARP1, as reported 
for p57 and myogenin in Supplementary Fig. S4.
PARP1 interacts with the regulatory regions of p57 and myogenin. To explore the molecular 
mechanism by which PARP1 represses gene expression in differentiating muscle cells, we performed a chro-
matin immunoprecipitation (ChIP) analysis of PARP1 interaction with chromatin during differentiation. We 
focused our attention on the p57 distal regulatory region KVDMR1 and on myogenin promoter, critical and 
well-characterized elements for the differentiation-dependent expression of the two genes. As regards KvDMR1, 
we have previously demonstrated that this region, unlike p57 promoter, is directly bound by MyoD upon differ-
entiation and that its epigenetic status influences the recruitment of the myogenic factor and the consequent dis-
ruption of a repressive chromatin loop with p57  promoter15,17–19. Concerning myogenin promoter, this region has 
always been a paradigmatic model for the study of MyoD-induced transcription and has been characterized in 
great detail for the dynamics of histone modifications and transcription factor binding during  differentiation67. 
Nuclear extracts were collected from undifferentiated and differentiated cells and analysed for the enrichment 
of KvDMR1 and myogenin promoter in PARP1 immunoprecipitates. Rhodopsin (Rho) promoter was used as a 
negative control, as previously  reported45. As shown in Fig. 3, PARP1 binds to both KVDMR1 and myogenin 
promoter, but not to Rho promoter, suggesting its involvement in the regulation of p57 and myogenin transcrip-
tion. Moreover, in line with the decrease of the total protein levels observed during differentiation, the associa-
tion of PARP1 with both regions was reduced in differentiated respect to undifferentiated cells, supporting the 
hypothesis that the binding of the enzyme to the regulatory regions of p57 and myogenin might inhibit their 
induction. A ChIP assay for MyoD binding to the same regions confirmed our previous findings and indicated 
the recicprocal occupancy of these two proteins. Moreover, as reported in Supplementary Fig. S5, in undifferen-
tiated cells PARP1 also binds to p57 promoter and to an intragenic p57 regulatory region, which we have previ-
ously described to be regulated by MyoD, the first through and indirect  mechanism19 and the second through 
direct MyoD  binding15.
The presence of PARP1 interferes with MyoD binding to KvDMR1 and myogenin promoter. As 
mentioned above, the impairment of MyoD recruitment to its binding elements, due to chromatin restraints, 
is involved in the failure of MyoD-dependent gene activation in undifferentiated cells or in cells refractory 
to express some specific MyoD target genes. Considering that the association of PARP1 with KvDMR1 and 
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Figure 1.  PARP1 depletion boosts the induction of MyoD target genes during differentiation. (a) Western blot analysis of PARP1 
expression in C2.7 cell pools stably transduced with shPARP1 or with the empty vector (CTRL). Proteins were extracted from cells 
proliferating in growth medium (GM) or kept for 24 and 48 h in differentiation medium (DM 24 h and DM 48 h respectively. ERK1 
was used as an invariant control. One representative experiment of two independent ones is shown. Full length blots are presented in 
Fig. S8. (b) RT-qPCR analysis of p57, myogenin (MyoG), p21 and Mef2C expression in cells cultured as described in (a). Expression 
levels, relative to those of Tbp RNA, are reported as the mean ± SEM of six independent experiments. Statistical significance: 
p-value < 0.05 (*) and < 0.01 (**). 
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myogenin promoter declines during differentiation, in concomitance with the onset of MyoD recruitment, we 
speculated that PARP1 could repress p57 and myogenin expression by interfering with the binding of MyoD to 
their regulatory regions. To verify this hypothesis, we evaluated the relationship between PARP1 and MyoD 
association with KvDMR1 and myogenin promoter in cells silenced for PARP1 and in cells re-expressing PARP1 
compared to their respective controls. ChIP assays for the interaction of PARP1 or MyoD with KvDMR1 and 
myogenin promoter were performed in cells cultured in differentiation conditions, in which MyoD is normally 
recruited to these regions. As shown in Fig.  4, cells depleted of PARP1 show decreased PARP1 binding, as 
expected, while cells re-expressing PARP1 showed increased PARP1 binding to both regions. Remarkably, as 
shown in the same figure, the PARP1 recruitment inversely correlated with that of MyoD, suggesting that PARP1 
may act by hindering the MyoD binding to its targets.
PARP1 activity is not required for p57 and myogenin repression. To investigate the possible role of 
the enzyme activity in the observed effects, we first measured the total PAR levels during differentiation. Unex-
pectedly, as demonstrated by the western blot analysis reported in Fig. 5a, PARylation strongly increased upon 
the induction of differentiation, at the opposite of PARP1 levels. A comparable result was obtained using a differ-
ent protocol for cell lysis (Supplementary Fig. S6). Several hypotheses can be advanced to explain the observed 
increase (see “Discussion” Section). However, to address more directly whether PARylation was involved in the 
regulation of MyoD targets, we evaluated the dynamics of PAR accumulation on the p57 and myogenin regu-
latory regions during differentiation. In light of the technical difficulties reported for the study of chromatin 
PARylation and, in particular, considering that cell lysis can induce DNA damage and artificial PARylation of 
non-specific chromatin targets 68, we also analysed two additional regulatory regions, as negative and positive 
controls respectively. One is Rho promoter, that we have previously shown to be scarcely PARylated 45. The other 
one is Igf2 DMR1 (a differentially methylated region located upstream of the Igf2 promoter 1), which was previ-
ously reported to be susceptible to PARylation 69. As reported in Fig. 5b, while PARylation was constantly low at 
Rho promoter, it increased at Igf2 DMR1 during differentiation, reflecting at least in part the trend of the global 
PARylation observed in cell extracts. In contrast, the PAR levels at p57 and myogenin regulatory regions, which 
were only a little higher respect to Rho promoter, did not change upon differentiation. The lack of correlation 
between the transcriptional activity of the two genes and the PAR levels at KVDMR1 and myogenin promoter 
represented a first indication that PARylation did not play a role in their regulation.
To directly address whether the transcriptional control of p57 and myogenin by PARP1 was independent of 
the enzyme activity, we measured the expression of the two genes in myoblast cells induced to differentiate in 
the presence of pharmacological PARP inhibitors. To this end we used the small molecules ABT-888 (Veliparib) 
and AZD-2281 (Olaparib) two PARP inhibitors selective for PARP1 and PARP2 family  members70 and capa-
ble of strongly inhibiting PARylation at concentrations that do not affect cell  viability70,71. As expected, and as 
reported in Fig. 6 (left panels), either Veliparib or Olaparib treatment effectively abrogated global PAR levels in 
differentiating cells. However, the inhibition of the enzyme activity, unlike the depletion of the protein, did not 
promote, rather it slightly inhibited p57 and myogenin induction (Fig. 6), indicating that PARP1 represses the 
expression of the two genes through a catalytic-independent mechanism.
Interestingly, we noticed that the effect of Olaparib was more evident respect to that of Veliparib and also 
statistically significant. It is worth mentioning that Olaparib was reported not only to strongly inhibit PARP1 
activity, but also to cause the trapping of PARP1 on the  chromatin71,72. This effect, ascribed both to the inhibition 
of the enzyme activity and to the induction of a conformational change of  PARP172, was especially detected in 
the presence of DNA strand breaks. However, a slight, but detectable increase of PARP1 binding to chromatin 
was also observed in cells treated with Olaparib in the absence of DNA damaging  agents71. To verify whether 
Olaparib treatment affected PARP1 binding to MyoD targets, we performed ChIP assays in C2 cells differenti-
ated in the presence or absence of Olaparib treatment. Interestingly, as reported in Fig. 7, Olaparib treatment 
actually resulted in increased PARP1 binding to both KvDMR1 and myogenin promoter in differentiated cells. 
The molecular mechanisms of PARP1 trapping by PARP inhibitors have not been completely clarified  yet73, nor 
we can say whether the increased PARP1 binding to muscle genes after Olabarib treatment involves its trap-
ping on DNA breaks. This issue will certain deserve further investigation. However, and remarkably, increased 
PARP1 binding correlated with decreased MyoD recruitment to p57 and myogenin regulatory regions (Fig. 7), 
similarly to what observed when PARP1 was re-expressed in shPARP1 cells (Fig. 4) and in line with the impaired 
induction of the two genes (Fig. 6). These findings not only substantiated the inhibitory role of PARP1 in MyoD 
binding to chromatin, but also confirmed that this function does not require the enzyme activity or even that it 
is reinforced by its inactivity.
PARP1 impairs the accumulation of H3K4me3 at MyoD binding regions. Although it cannot be 
excluded that PARP1 acts by directly hindering MyoD recruitment to its binding sequences, it is reasonable to 
hypothesize that PARP1 may act by maintaining a repressive chromatin environment at genes that have to be 
induced at the onset of differentiation. PARP1 affects chromatin function through multiple strategies, including 
the alteration of some types of histone modifications, among which the tri-methylation of lysine 4 in histone 
H3 (H3K4me3), an active chromatin mark. PARP1 was reported to affect H3K4me3 in a complex manner. In 
particular, in its active state, the enzyme inhibits the H3K4me3 histone demethylase KDM5B, promoting the 
accumulation of this modification on multiple gene  promoters48. On the other hand, inactive PARP1 inhibits 
the H3K4 methyltransferase MLL1, and prevents H3K4me3 accumulation at the gene promoter of interleukin 6, 
repressing its  expression74. By inspecting the ChIP-seq data for muscle cells from ENCODE/Caltech, we noticed 
that the levels of H3K4me3 at KvDMR1 and myogenin promoter, were lower in undifferentiated respect to dif-
ferentiated cells. To assess the possible relationship of these chromatin changes with the differential binding 
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of PARP1, we performed ChIP assays for H3K4me3 in cells re-expressing PARP1 compared to silenced cells. 
Remarkably, as shown in Fig. 8, the accumulation of H3K4me3 at KvDMR1 and myogenin promoter was reduced 
upon the re-expression of PARP1, presumably as a result of its increased binding to chromatin in differentiating 
cells (as shown above in Fig. 4). In line with this evidence, identical and specular results were obtained when 
comparing Olaparib-treated with untreated cells and when comparing PARP1-silenced cells with their control, 
respectively (Supplementary Fig. S7). All these findings suggest the existence of a functional link between the 
loss of PARP1 binding, the accumulation of the activating histone modification H3K4me3, the recruitment of 
MyoD and the up-regulation of MyoD-target genes (see the model depicted in Fig. 9).
Discussion
In the present work we provide evidence, for the first time, that PARP1 participates in the control of gene expres-
sion during muscle differentiation and, in particular, we show that PARP1, independently of its enzymatic activity, 
functions as negative regulator of MyoD binding to chromatin. These findings not only add new insight into 
the transcriptional control of muscle differentiation, but also expand our knowledge about the differentiation-
related functions of PARP1.
We found that PARP1 depletion promotes the induction of p57, myogenin, Mef2C and p21, while PARP1 
re-expression reduces their up-regulation. The small, yet statistically significant changes in gene expression, 
observed when PARP1 levels are modulated, are accompanied by similarly small changes in later events of dif-
ferentiation, such as the fusion into myotubes. However, it is conceivable that a refined modulation of muscle 
gene expression may play a critical role during in vivo processes of myogenesis, such as muscle development or 
regeneration, which take place over more extended time periods respect to in vitro differentiation.
Importantly, our finding that PARP1 affects at least four different genes, which are known to be induced 
with different kinetics and through different molecular mechanisms, but which share the property to be directly 
targeted by MyoD, strongly supports a functional interference of PARP1 with MyoD-dependent transcription.
PARP1-dependent gene repression correlates with the presence of the protein on the regulatory regions 
of the affected genes, as demonstrated by a wide-range analysis of gene expression in MCF7 tumor  cells75 and 
in human embryonic stem  cells76 as well as for specific genes such as PARP1 itself in Ewing’s sarcoma  cells77 
and IL6 in the RAW 264.7 macrophage cell line 74. Accordingly, we found that PARP1 directly interacts both 
with myogenin promoter, the prototypical regulatory region targeted by  MyoD67, and with KvDMR1, a distant 
imprinting control region that we identified as a MyoD-responsive element involved in the control of p57 induc-
tion during  differentiation17–19. Moreover, consistent with the decrease of total PARP1 levels and with the need 
of relieving a negative control from these genes to allow their up-regulation, PARP1 binding was significantly 
reduced in differentiated respect to undifferentiated cells. It is worth noticing that the loss of PARP1, although 
necessary, does not appear sufficient for inducing MyoD targets, as indicated by the observation that the basal 
expression of these genes, in undifferentiated cells, was not up-regulated upon PARP1 depletion. However, this 
is not surprising when considering that MyoD, although expressed since before differentiation, is kept inactive 
by interacting proteins and post-translational modifications induced by proliferation  pathways65. For this reason, 
although it is possible that PARP1 participates in the repression of MyoD-targets in undifferentiated cells, the 
principal suggestion emerging from our data is that the role of PARP1 is to limit the up-regulation of muscle 
genes during differentiation (see the model depicted in Fig. 9).
Depending on the regulatory context, PARP1 can either promote or suppress transcription and each of these 
effects can be either dependent or independent of its catalytic  activity78. In this regard, much more information 
has been gathered about the catalytic-dependent respect to the catalytic-independent functions of PARP1. In 
light of the down-regulation of PARP1 expression, we were surprised to see a strong induction of PARylation 
during differentiation. We cannot say at this moment whether increased PARylation can be ascribed to a strong 
activation of the small amount of residual PARP1 or to other PARP family members. Concerning the molecular 
mechanism inducing PARP activity, one possible explanation is the accumulation of DNA strand breaks, which 
has long been noticed in differentiated myotubes as well as in other types of terminally differentiated  cells79. 
Although the possible role of this phenomenon in differentiation processes remains hypothetical, it has been 
suggested that the accumulation of DNA damage involves a reduced efficiency of DNA repair at global genome 
level, yet its maintenance at active  genes80. This phenomenon is certainly interesting and will deserve further 
investigation. However, in the context of the present work we obtained evidence that the enzyme activity is not 
Figure 2.  PARP1 re-expression reduces the induction of MyoD target genes during differentiation. (a) Western 
blot analysis of PARP1 and MyoD levels in shPARP1 cells stably transfected with the PARP1 expression 
vector (shPARP1-PARP1), compared to shPARP1 control cells transfected with the empty vector (shPARP1-
CTRL). Proteins were extracted from cells proliferating in growth medium (GM) or kept for 24 and 48 h 
in differentiation medium (DM 24 h and DM 48 h respectively). ERK1 was used as an invariant control. 
One representative experiment of two independent ones is shown. Full length blots are presented in Fig. S9. 
(b) RT-qPCR analysis of p57, myogenin (MyoG), p21 and Mef2C induction in shPARP1-PARP1 compared 
to shPARP1-CTRL cells. RNA levels were analysed 24 and 48 h after the shift to differentiation medium. 
Expression levels, relative to those of Tbp RNA and expressed as fold change respect to the control at 24 h, are 
reported as the mean ± SEM of three independent experiments. Statistical significance: p-value < 0.05 (*), < 0.01 
(**), < 0.001 (***). (c) Quantification of the immunofluorescence analysis of MHC-positive myotubes in CTRL, 
shPARP1, shPARP1-CTRL and shPARP1-PARP1 cells. The percentage of nuclei in MHC-positive cells was 
calculated as the ratio of the nuclei contained in MHC-positive cells to total number of nuclei, 72 h after shift to 
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required for PARP1 to restrain p57 and myogenin induction. At first, we observed that the levels of PARylation 
at the regulatory regions of these genes do not correlate with their transcriptional activity. Most importantly, the 
inhibition of PARP activity by each of two different inhibitors, Veliparib and Olaparib, does not increase myogenin 
and p57 expression as PARP1 depletion does. It is important to notice that, while Veliparib treatment does not 
affect their expression, Olaparib treatment even represses their induction. The effect of Olaparib, that we found 
to correlate with the maintenance of inactive PARP1 at p57 and myogenin regulatory regions, possibly due to its 
trapping, further reinforced the suggestion that PARP1 represses the expression of these genes by affecting the 
chromatin function in a catalytic-independent manner.
Regarding the molecular mechanism of repression, we observed that the binding of PARP1 inversely cor-
relates with that of MyoD. This kind of effect is opposite to that observed for other transcription factors, such 
as NF-KB81 and  SOX252, whose binding to chromatin is enhanced by inactive PARP1. In light of our previous 
finding that MyoD functionally interacts with CTCF at KvDMR1, to induce p57  expression18, and considering 
the existence of an interplay between PARP1 and CTCF in promoting chromatin insulation and in repressing 
ribosomal  transcription82 , we wondered if CTCF was involved in the observed effects of PARP1 on MyoD 
function. However, it is very unlikely that this is the case, since PARP1-dependent regulation of CTCF requires 
CTCF  PARylation83, whereas we found that the ability of MyoD to activate its targets is not influenced by the 
inhibition of PARP activity.
Interestingly, although active PARP1 inhibits the histone demethylase KDM5B through its PARylation, which 
results in the accumulation of the active mark H3K4me3 at several genomic  regions48, it has been reported 
that inactive PARP1 prevents the deposition of the same histone modification at IL-6 promoter, through the 
Figure 3.  PARP1 interacts with the regulatory regions of the MyoD target genes p57 and myogenin. ChIP-qPCR 
analysis for PARP1 (a) and MyoD (b) binding to KvDMR1, myogenin promoter (MyoG prom) and Rhodopsin 
promoter (Rho prom), used as a negative control, during C2.7 cell differentiation. Samples were prepared from 
undifferentiated cells proliferating in growth medium (GM), and from differentiated cells kept for 24 or 48 h in 
differentiation medium (DM 24 h and DM 48 h respectively) and immunoprecipitated either with the protein 
specific antibodies (IP samples) or with control IgG. Protein binding to the indicated regions is expressed as 
percentage of input. The mean ± SEM of four independent experiments is reported for PARP1 ChIP. Statistical 
significance: p-value < 0.05 (*) and < 0.01 (**). A representative experiment for MyoD ChIP is shown, with error 
bars corresponding to the mean of each sample analyzed in triplicate.
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inhibition of the histone methyltransferase MLL1, leading to the suppression of IL-6  expression74. In line with 
this report, we found that the accumulation of PARP1 inversely correlates with that of H3K4me3 at KvDMR1 
and myogenin promoter. Since MLL1 is highly expressed in muscle cells and seems to regulate both proliferation 
and  differentiation84, the possibility of its functional interaction with PARP1 during myogenesis will deserve 
further investigation. Although it is conceivable that the decreased levels of H3K4me3, by promoting a repressive 
chromatin environment, are responsible for the PARP1-dependent exclusion of MyoD from its targets, we still 
cannot exclude that the accumulation of H3K4me3 is a result of transcriptional activation consequent to MyoD 
binding. In fact, while the presence of H3K4me3 is clearly associated with gene activity, some lines of evidence 
suggest that this modification does not play an instructive role in transcription but, rather, is a result of  this85. An 
alternative hypothesis for explaining the interference of PARP1with MyoD binding could be related to the role of 
PARP1 as a structural component of the chromatin and to its ability to directly interact with nucleosomes. In fact, 
in the absence of the enzyme activity and, similarly to histone H1, PARP1 was found to promote the compaction 
of in vitro-assembled  chromatin39. Interestingly, it has been recently suggested that inactive PARP1 can enhance 
the chromatin binding of the pioneer transcription factor SOX2 by distorting nucleosomal  DNA52. Actually, the 
effect exerted by PARP1 on MyoD binding is the opposite. However, it is possible to imagine that the ability of 
PARP1 to alter the structural features of nucleosomal DNA may affect in different ways the binding of different 
transcription factors. The exact mechanisms by which inactive PARP1 affects the ability of MyoD to bind and 
transactivate its targets await an in depth investigation aimed at defining in detail the status of the chromatin 
accessibility, the pattern of additional histone modifications and the structural features of nucleosomes.
In summary, this work reveals that PARP1 affects the ability of MyoD to access at least some of its chromatin 
targets during differentiation, highlighting a novel player in the epigenetic control of muscle differentiation. In 
this regard, it would be exciting to be able to generalize the present findings through a comparative analysis of 
MyoD and PARP1 binding throughout the genome, in relation with chromatin dynamics and gene expression, 
during the differentiation process. It would also be interesting to examine the possible role of PARP1-dependent 
chromatin alterations in muscle pathologies, such rhabdomyosarcoma, in which the failure to activate some 
myogenic targets correlates with the defective MyoD binding to their regulatory  regions24. It is worth mentioning 
Figure 4.  PARP1 impairs MyoD binding to p57 and myogenin regulatory regions. ChIP-qPCR analysis for 
PARP1 and MyoD binding to KvDMR1 and myogenin promoter (MyoG prom). Samples were prepared from 
CTRL, shPARP1, shPARP1-CTRL and shPARP1-PARP1 cells, collected 24 h after the shift to differentiation 
medium, and then immunoprecipitated with PARP1 or MyoD antibodies (αPARP1 and αMyoD, IP samples), as 
well as with control IgG. Protein binding is expressed as percentage of input and represents the mean ± SEM of 
three independent experiments. Statistical significance: p-value < 0.05 (*).
10
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that the PARP inhibitor Olaparib, already approved for the therapy of some tumor types defective for homologous 
recombination DNA repair, is currently under investigation for the possible treatment of inflammatory and oxi-
dative stress  diseases86. In this regard, Olaparib was reported to improve the mitochondrial function in skeletal 
muscle cells, suggesting the possible clinical use of this inhibitor to treat muscle dysfunctions associated with 
mitochondrial  defects64. Therefore, the attainment of an integrated picture of the complex and multiple roles of 
PARP1 in muscle is extremely important for increasing our awareness of the pleiotropic effects of modulating 
PARP1 function in different pathophysiological contexts.
Methods
Cell cultures. Mouse C2.7 muscle cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) 
(Gibco) supplemented with 10% fetal bovine serum (FBS) (Microgem) and maintained sub-confluent in order 
to avoid differentiation. To induce MyoD activity and differentiation, cells were shifted to DMEM supplemented 
with 0.5% FBS (differentiation medium) and collected 24 or 48 h later, as indicated. 1 µM Olaparib (Selleck-
chem) or 1 µM Veliparib (Selleckchem) were administered to cell cultures at the time of the shift to differentia-
tion medium.
Generation of stably knocked‑ down cell lines and cell transfections. The shPARP1 retroviral vec-
tor was previously constructed, as  described45.
Empty (Control) and shPARP-1-expressing retroviruses were produced by transfecting the constructs into 
BOSC 23 packaging cells as previously  reported45. For the stable knock-down of PARP1, C2.7 cells were incu-
bated with the BOSC23 retroviral supernatant supplemented with 4 μg/ml polybrene for 8 h and then re-fed 
with fresh medium. 48 h after infection cells where seeded at low density in selective medium containing 2.5 μg/
ml of puromycin (Sigma) and, after about one week, the surviving clones were pooled together and cultured as 
indicated for C2.7 cells.
Stable re-expression of PARP1 was obtained by co-transfecting the puc19-PARP1 plasmid, coding for human 
PARP1 and kindly provided by Prof. Paola Caiafa, with the pSV2hygro plasmid, coding for the hygromycin 
resistance, in ratio 10:1, into shPARP1 C2.7 cells, using Lipofectamine 2000 reagent (Invitrogen) according to 
the manufacturer’s instructions. 48 h later, cells transfected with either puc19-PARP1 plasmid or with the empty 
vector puc19 were seeded in selective medium containing 2.5 μg/ml of hygromycin (Sigma) and, after two weeks, 
the surviving clones were pooled together and cultured as indicated for C2.7 cells.
Western Blot assays. Cells were collected in RIPA buffer (NaCl 150 mM, NP-40 1%, Sodiumdeoxycholate 
0.5%, SDS 0.1% and TRIS–HCl pH 8.0 50 mM) or in Laemmli 1X buffer (TRIS–HCl ph 6.8 60 mM, SDS 2%, 
glycerol 10%, β-mercaptoethanol 12.5%, Toluidine Blue 0.1 g). Proteins were resolved by electrophoresis in 8% 
polyacrylamide SDS-PAGE and transferred to nitrocellulose membranes by electro-blotting. Membranes were 
blocked in 2% non-fat dry milk in TBS containing 0.05% Tween 20 for 1 h at room temperature and incubated 
with the primary antibodies overnight at 4 °C, then washed three times and incubated with peroxidase-conju-
gated anti-mouse or anti-rabbit secondary antibodies (Bio-Rad). Proteins were detected using the ECL chemi-
luminescence system (Cyanagen).
The following primary antibodies used for western blot were purchased from Santa Cruz Biotechnology: anti-
PARP1 (H-250, sc-7150), anti-PAR (10H, sc-56198), anti-p57 (H-91, sc-8298) and anti-ERK1 (C-16, sc-093). 
The F5D hybridoma supernatant was used for myogenin.
Gene expression analysis. Total RNA was extracted using the High Pure RNA Isolation Kit according to 
the manufacturer’s instructions (Roche Diagnostics) and 500 ng were reverse transcribed with the iScript cDNA 
Synthesis Kit (Bio-Rad). Realtime-PCR (qPCR) reactions were performed in 10 μl of reaction buffer containing 
1 μl of diluted cDNA in 9 μl of GoTaq qPCR Master Mix (Promega) containing each primer at the optimized 
final concentration (150-250 nM). The reaction was performed in the termocycler “MiniOpticon Real-Time 
PCR detection system” (Bio-Rad) or "CFX96 Real-Time PCR detection system" (Bio-Rad). The primer pair 
efficiency, the normalized expressions (ΔΔCt) and the Standard Error for the Normalized Expression were deter-
mined with CFX ManagerTM software (Bio-Rad).
The following primer sets were used:
for p57
Figure 5.  PAR levels at the regulatory regions of the MyoD target genes p57 and myogenin do not change 
during differentiation. (a) Western blot analysis of PARylated proteins in undifferentiated C2.7 myoblasts 
proliferating in growth medium (GM) and in differentiated C2.7 myotubes cultured for 24 or 48 h in 
differentiation medium (DM). PARylated proteins were detected with the anti-PAR antibody. ERK1 was used 
as an invariant control. Full length blots are presented in Fig. S10. (b) ChIP-qPCR analysis for PAR levels 
at KvDMR1, myogenin promoter (MyoG prom), Rhodopsin promoter (Rho prom), and Igf2 Differentially 
Methylated region (Igf2 DMR1) during C2.7 cell differentiation. Samples were prepared from undifferentiated 
cells proliferating in growth medium (GM), and from differentiated cells kept for 24 h in differentiation medium 
(DM) and immunoprecipitated either with PAR antibody (IP samples) or with control IgG. Protein binding is 
expressed as percentage of input and represents the mean ± SEM of four independent experiments for KvDMR1 
and MyoG prom and of three independent experiments for Rho prom and Igf2 DMR1. Statistical significance: 
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F: 5′-AAC TTC CAG CAG GAT GTG CC-3’
R: 5′-CAT CCA CTG CAG ACG ACC AG-3′;
for myogenin
F: 5′-GTC TCT TCC TGA AGC CAG TTGCG-3′
R: 5′-TGC AAA TGC TTG GCC CCC AGAG-3′;
for p21
F: 5′-AGC AGC CGA GAG GTG TGA GC-3’
R: 5′-TGG ACA TGG TGC CTG TGG CTCCT-3’
for Mef2C
F: 5′-TCC AAG TGC AGG TAA CAC AG-3’
R: 5′-TTG CCG TAT CCA TTC CCT G-3’
for Tbp, used as housekeeping gene
Figure 6.  PARP activity is not required for the repression of p57 and myogenin induction. Left panels: western 
blot analyses of PAR levels in C2.7 differentiating in the presence of either Veliparib (upper) or Olaparib (lower). 
Protein samples were prepared from cells proliferating in growth medium (GM) and from cells shifted to 
differentiation in medium (DM), in the presence of 1 µM Veliparib, 1 µM Olaparib or the control vehicle DMSO 
(vehicle) and kept for 24 and 48 h. PARylated proteins were detected with the anti-PAR antibody. ERK1 was 
used as an invariant control. One representative of three independent experiments is shown. Full length blots 
are presented in Fig. S11. Right panels: RT-qPCR analysis of p57 and myogenin (MyoG) expression in C2.7 cells 
differentiated in the presence of Veliparib (upper right) or Olaparib (lower right), as described for western blot 
analyses. Expression levels, relative to those of Tbp RNA and expressed as fold change respect to the control 
at 24 h represent the mean ± SEM of three independent experiments. Statistical significance: p-value < 0.05 (*) 
and < 0.01 (**); ns stands for not significant.
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F:5′-GGC GGT TTG GCT AGG TTT -3’
R: 5′-GGG TTA TCT TCA CAC ACC ATG-3’.
Chromatin immunoprecipitation (ChIP) assays. Nuclear lysates were prepared as previously 
 described19. After determining the DNA concentrations, each chromatin sample was divided into aliquots cor-
responding to 150, 75 and 50 μg of DNA.
ChIP assays for PARP1, PAR and MyoD were carried out as previously described using 150 µg of chromatin 
for MyoD, and 75 µg for PARP1 and PAR. ChIP assays for H3K4me3 were performed using 50 µg of chromatin 
and Magna ChIP Protein A Magnetic Beads (Millipore) according to the manufacturer’s instructions.
The following antibodies were used for immunoprecipitation: anti-PARP1 (ALX-210-302, Alexis Bio-
chemicals); anti-PAR (4335-MC-100, Trevigen), anti-MyoD (G-1, sc-377460, Santa Cruz Biotechnology), anti 
H3K4me3 (07-473, Millipore), normal mouse IgG Antibody (12–371, Millipore) and normal rabbit IgG Antibody 
(12-370, Millipore).
Figure 7.  Olaparib treatment results in increased PARP1 binding and decreased MyoD recruitment to p57 and 
myogenin regulatory regions. ChIP-qPCR analysis for PARP1 and MyoD binding to KvDMR1 and myogenin 
promoter (MyoG prom). Samples were prepared from C2.7 cells collected 24 h after the shift to differentiation 
medium in the presence of either 1 µM Olaparib or the control vehicle DMSO (VEHICLE), and then 
immunoprecipitated as described in Fig. 4. Protein binding is expressed as percentage of input and represents 
the mean ± SEM of three independent experiments. Statistical significance: p-value < 0.05 (*).
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qPCR analysis was performed in triplicate for each The following primer sets were used for qPCR analysis:
for KvDMR1
F: 5′-GCA CAA GTC GCA AGT CCG CG-3’
R: 5′-ATG GAG CCC AGC CGC GAA AG-3;
for myogenin promoter
F: 5′-TGG CAG GAA CAA GCC TTT TGCGA-3’
R: 5′-AGT CCG CTC ATA GCC CGG GG-3′;
for Rho promoter
F: 5′-TTG TCA ACT GGA GCC ATG TG-3’
R: 5′-GTG TCT CAT CTT GTC TGC CC-3’
for Igf2 DMR1
F: 5′-TGG AAT GAG GAA CAT CAC CA-3’
R: 5′-TCT ATC CCT GGC TTT TCT GG-3’
Statistical analysis. For chart making and for statistical analysis, comparisons were performed using para-
metric paired Student’s t-test analysis with a confidence interval of 95%, using GraphPad Prism® graphic and 
statistical software. Statistical significance is shown as p < 0.05 (*) or p < 0.01 (**) or p < 0.001 (***).
Figure 8.  PARP1 re-expression impairs H3K4me3 accumulation at p57 and myogenin regulatory regions. 
ChIP-qPCR analysis for H3K4me3 association to KvDMR1 and myogenin promoter. shPARP1 cells stably 
re-expressing PARP1 (PARP1) and from shPARP1 control cells (CTRL) were collected 24 h after the shift to 
differentiation medium and samples were immunoprecipitated either with the H3K4me3 antibody (IP samples) 
or with the control IgG. Values are expressed as percentages of input and represent the mean ± SEM of three 
independent experiments. Statistical significance: p-value < 0.05 (*) and < 0.01 (**).
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